Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | QPCT | Q16769 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.35 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404117 | 0.89 | CYP3A4 (0.45) | CYP26A1CYP3A4MAPTPOLBKMT2A | |
| SCHEMBL28285780 | 0.74 | KMT2A (0.58) | KMT2AMEN1ALDH1A1USP2 | |
| SCHEMBL5443725 | 0.72 | CYP19A1 (0.50) | CYP3A4CYP11B2CYP11B1CYP19A1CYP1A2 | |
| SCHEMBL27482733 | 0.72 | CYP26A1 (0.42) | CYP26A1CYP3A4MAPTPOLBKMT2A | |
| SCHEMBL7075844 | 0.70 | CYP11B1 (0.46) | CYP26A1CYP3A4MAPTKMT2ACYP11B2 | |
| SCHEMBL5991144 | 0.69 | NOS1 (0.44) | CYP26A1CYP19A1QPCT | |
| SCHEMBL27641960 | 0.67 | KIF11 (0.50) | MAPTPOLBKMT2AMEN1TSHR | |
| SCHEMBL27784030 | 0.67 | CA1 (0.47) | KMT2A | |
| SCHEMBL27554657 | 0.66 | MAPT (0.66) | CYP3A4MAPTKMT2AQPCTCYP1A2 | |
| SCHEMBL28644193 | 0.66 | TAAR1 (0.54) | CYP3A4MAPTPOLBKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1833481-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION | 2006-09-21 | — | — | US | disclosed |
| WO-2006065794-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | FNTB, FNTA, FDPS | CYP26A1 902/4885CYP3A4 2289/4885MAPT 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.